Antony Mattessich | BiotechTV

top of page

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program...

Company News

Feb 26

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.

Company News

Jun 12, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Follow BiotechTV

Sponsors

Sponsor Spotlight